Trial Profile
Dual-immunotherapy and short-course medium-dose radiotherapy, followed by surgery for tumor microenvironment modification in early stage NSCLC
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 25 May 2021
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms DIRECT
- 25 May 2021 New trial record